Erythromycin: an alternative for the management of oral mucositis?
Oral mucositis (OM) is an important acute adverse effect of anticancer therapy. This condition presents high morbidity and may lead to the suspension of anticancer therapy. We reviewed the literature on the pathobiology of OM and the properties of erythromycin (EM), to consider the possibility of it...
Gespeichert in:
| Veröffentlicht in: | Medicina oral, patología oral y cirugía bucal patología oral y cirugía bucal, 2022-09, Vol.27 (5), p.e452-e459 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e459 |
|---|---|
| container_issue | 5 |
| container_start_page | e452 |
| container_title | Medicina oral, patología oral y cirugía bucal |
| container_volume | 27 |
| creator | Teixeira, D-S Louzeiro, G-C Figueiredo, M-A Cherubini, K Salum, F-G |
| description | Oral mucositis (OM) is an important acute adverse effect of anticancer therapy. This condition presents high morbidity and may lead to the suspension of anticancer therapy.
We reviewed the literature on the pathobiology of OM and the properties of erythromycin (EM), to consider the possibility of its use for the prevention and treatment of OM. We searched the PubMed, Scopus and Web of Science databases and selected complete articles published in English or Spanish that met the inclusion criteria. The search terms "erythromycin", "inflammation", "immunomodulation" and "oral mucositis" were used.
The control of free radicals, transcription factors and pro-inflammatory cytokines has been considered as the key to the management of OM. EM has the ability to modulate oxidative stress, acts on the transcriptional system and inhibits the production of several cytokines that have been directly implicated in OM pathobiology.
The present review suggests that EM could be effective in the treatment of OM. Experimental studies investigating the use of EM in OM should be encouraged. |
| doi_str_mv | 10.4317/medoral.25439 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9445611</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2678423976</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-b8773262f5bf7de2c750582c7a73b6b7a9323191b237a94943380fd38fe044043</originalsourceid><addsrcrecordid>eNpVUD1PwzAUtBCIQmFkRRlZUmw_x44ZQFCVD6kSC8yWk9qtURIXO6nUf09KS1WmO-md7u4dQlcEjxgQcVubmQ-6GtGMgTxCZ4TLPOWS8eMDPkDnMX5hDIIIfooGkG0IxWfoaRLW7SL4el265i7RTaKr1oRGt25lEutD0i5MUutGz01tmjbxNtnkJXVX-uhaFx8u0InVVTSXOxyiz-fJx_g1nb6_vI0fp2kJDNq0yIUAyqnNCitmhpYiw1negxZQ8EJoCRSIJAWFnjPJAHJsZ5BbgxnDDIbofuu77Ir-67Jv0xdRy-BqHdbKa6f-Xxq3UHO_UpKxjBPSG9zsDIL_7kxsVe1iaapKN8Z3UVEuckZBCt5L0620DD7GYOw-hmC12V3tdle_u_f668Nue_Xf0PADP8-AMQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2678423976</pqid></control><display><type>article</type><title>Erythromycin: an alternative for the management of oral mucositis?</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Teixeira, D-S ; Louzeiro, G-C ; Figueiredo, M-A ; Cherubini, K ; Salum, F-G</creator><creatorcontrib>Teixeira, D-S ; Louzeiro, G-C ; Figueiredo, M-A ; Cherubini, K ; Salum, F-G</creatorcontrib><description>Oral mucositis (OM) is an important acute adverse effect of anticancer therapy. This condition presents high morbidity and may lead to the suspension of anticancer therapy.
We reviewed the literature on the pathobiology of OM and the properties of erythromycin (EM), to consider the possibility of its use for the prevention and treatment of OM. We searched the PubMed, Scopus and Web of Science databases and selected complete articles published in English or Spanish that met the inclusion criteria. The search terms "erythromycin", "inflammation", "immunomodulation" and "oral mucositis" were used.
The control of free radicals, transcription factors and pro-inflammatory cytokines has been considered as the key to the management of OM. EM has the ability to modulate oxidative stress, acts on the transcriptional system and inhibits the production of several cytokines that have been directly implicated in OM pathobiology.
The present review suggests that EM could be effective in the treatment of OM. Experimental studies investigating the use of EM in OM should be encouraged.</description><identifier>ISSN: 1698-6946</identifier><identifier>ISSN: 1698-4447</identifier><identifier>EISSN: 1698-6946</identifier><identifier>DOI: 10.4317/medoral.25439</identifier><identifier>PMID: 35717620</identifier><language>eng</language><publisher>Spain: Medicina Oral S.L</publisher><subject>Cytokines ; Erythromycin - therapeutic use ; Humans ; Mucositis ; Review ; Stomatitis - drug therapy</subject><ispartof>Medicina oral, patología oral y cirugía bucal, 2022-09, Vol.27 (5), p.e452-e459</ispartof><rights>Copyright: © 2022 Medicina Oral S.L. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445611/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445611/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35717620$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Teixeira, D-S</creatorcontrib><creatorcontrib>Louzeiro, G-C</creatorcontrib><creatorcontrib>Figueiredo, M-A</creatorcontrib><creatorcontrib>Cherubini, K</creatorcontrib><creatorcontrib>Salum, F-G</creatorcontrib><title>Erythromycin: an alternative for the management of oral mucositis?</title><title>Medicina oral, patología oral y cirugía bucal</title><addtitle>Med Oral Patol Oral Cir Bucal</addtitle><description>Oral mucositis (OM) is an important acute adverse effect of anticancer therapy. This condition presents high morbidity and may lead to the suspension of anticancer therapy.
We reviewed the literature on the pathobiology of OM and the properties of erythromycin (EM), to consider the possibility of its use for the prevention and treatment of OM. We searched the PubMed, Scopus and Web of Science databases and selected complete articles published in English or Spanish that met the inclusion criteria. The search terms "erythromycin", "inflammation", "immunomodulation" and "oral mucositis" were used.
The control of free radicals, transcription factors and pro-inflammatory cytokines has been considered as the key to the management of OM. EM has the ability to modulate oxidative stress, acts on the transcriptional system and inhibits the production of several cytokines that have been directly implicated in OM pathobiology.
The present review suggests that EM could be effective in the treatment of OM. Experimental studies investigating the use of EM in OM should be encouraged.</description><subject>Cytokines</subject><subject>Erythromycin - therapeutic use</subject><subject>Humans</subject><subject>Mucositis</subject><subject>Review</subject><subject>Stomatitis - drug therapy</subject><issn>1698-6946</issn><issn>1698-4447</issn><issn>1698-6946</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUD1PwzAUtBCIQmFkRRlZUmw_x44ZQFCVD6kSC8yWk9qtURIXO6nUf09KS1WmO-md7u4dQlcEjxgQcVubmQ-6GtGMgTxCZ4TLPOWS8eMDPkDnMX5hDIIIfooGkG0IxWfoaRLW7SL4el265i7RTaKr1oRGt25lEutD0i5MUutGz01tmjbxNtnkJXVX-uhaFx8u0InVVTSXOxyiz-fJx_g1nb6_vI0fp2kJDNq0yIUAyqnNCitmhpYiw1negxZQ8EJoCRSIJAWFnjPJAHJsZ5BbgxnDDIbofuu77Ir-67Jv0xdRy-BqHdbKa6f-Xxq3UHO_UpKxjBPSG9zsDIL_7kxsVe1iaapKN8Z3UVEuckZBCt5L0620DD7GYOw-hmC12V3tdle_u_f668Nue_Xf0PADP8-AMQ</recordid><startdate>20220901</startdate><enddate>20220901</enddate><creator>Teixeira, D-S</creator><creator>Louzeiro, G-C</creator><creator>Figueiredo, M-A</creator><creator>Cherubini, K</creator><creator>Salum, F-G</creator><general>Medicina Oral S.L</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220901</creationdate><title>Erythromycin: an alternative for the management of oral mucositis?</title><author>Teixeira, D-S ; Louzeiro, G-C ; Figueiredo, M-A ; Cherubini, K ; Salum, F-G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-b8773262f5bf7de2c750582c7a73b6b7a9323191b237a94943380fd38fe044043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cytokines</topic><topic>Erythromycin - therapeutic use</topic><topic>Humans</topic><topic>Mucositis</topic><topic>Review</topic><topic>Stomatitis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Teixeira, D-S</creatorcontrib><creatorcontrib>Louzeiro, G-C</creatorcontrib><creatorcontrib>Figueiredo, M-A</creatorcontrib><creatorcontrib>Cherubini, K</creatorcontrib><creatorcontrib>Salum, F-G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicina oral, patología oral y cirugía bucal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Teixeira, D-S</au><au>Louzeiro, G-C</au><au>Figueiredo, M-A</au><au>Cherubini, K</au><au>Salum, F-G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erythromycin: an alternative for the management of oral mucositis?</atitle><jtitle>Medicina oral, patología oral y cirugía bucal</jtitle><addtitle>Med Oral Patol Oral Cir Bucal</addtitle><date>2022-09-01</date><risdate>2022</risdate><volume>27</volume><issue>5</issue><spage>e452</spage><epage>e459</epage><pages>e452-e459</pages><issn>1698-6946</issn><issn>1698-4447</issn><eissn>1698-6946</eissn><abstract>Oral mucositis (OM) is an important acute adverse effect of anticancer therapy. This condition presents high morbidity and may lead to the suspension of anticancer therapy.
We reviewed the literature on the pathobiology of OM and the properties of erythromycin (EM), to consider the possibility of its use for the prevention and treatment of OM. We searched the PubMed, Scopus and Web of Science databases and selected complete articles published in English or Spanish that met the inclusion criteria. The search terms "erythromycin", "inflammation", "immunomodulation" and "oral mucositis" were used.
The control of free radicals, transcription factors and pro-inflammatory cytokines has been considered as the key to the management of OM. EM has the ability to modulate oxidative stress, acts on the transcriptional system and inhibits the production of several cytokines that have been directly implicated in OM pathobiology.
The present review suggests that EM could be effective in the treatment of OM. Experimental studies investigating the use of EM in OM should be encouraged.</abstract><cop>Spain</cop><pub>Medicina Oral S.L</pub><pmid>35717620</pmid><doi>10.4317/medoral.25439</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1698-6946 |
| ispartof | Medicina oral, patología oral y cirugía bucal, 2022-09, Vol.27 (5), p.e452-e459 |
| issn | 1698-6946 1698-4447 1698-6946 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9445611 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Cytokines Erythromycin - therapeutic use Humans Mucositis Review Stomatitis - drug therapy |
| title | Erythromycin: an alternative for the management of oral mucositis? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T18%3A11%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erythromycin:%20an%20alternative%20for%20the%20management%20of%20oral%20mucositis?&rft.jtitle=Medicina%20oral,%20patolog%C3%ADa%20oral%20y%20cirug%C3%ADa%20bucal&rft.au=Teixeira,%20D-S&rft.date=2022-09-01&rft.volume=27&rft.issue=5&rft.spage=e452&rft.epage=e459&rft.pages=e452-e459&rft.issn=1698-6946&rft.eissn=1698-6946&rft_id=info:doi/10.4317/medoral.25439&rft_dat=%3Cproquest_pubme%3E2678423976%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2678423976&rft_id=info:pmid/35717620&rfr_iscdi=true |